Advertisement

Myogenic Ptosis

  • Natan D. Kahn
  • David A. Weinberg
Chapter

Abstract

Myogenic ptosis may present in children or adults. There is commonly reduced levator function and associated weakness of the extraocular, orbicularis oculi, and facial muscles. In some cases, one may find bulbar, limb, and respiratory muscle weakness, as well as a variety of other associated findings, such as frontal balding and polychromatophilic cataracts in myotonic dystrophy. Myogenic ptosis can frequently be diagnosed via muscle biopsy or genetic testing. Ptosis surgery may be quite effective, although frontalis slings are often ultimately necessary due to the progressive nature of myopathic ptosis in many or most cases.

Keywords

Myotonic Dystrophy Levator Muscle Frontalis Muscle Chronic Progressive External Ophthalmoplegia Levator Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hornblass A, Adachi M, Wolintz A, Smith B. Clinical and ultrastructural correlation in congenital and acquired ptosis. Ophthalmic Surg. 1976;7(1):69–76.PubMedGoogle Scholar
  2. 2.
    Frueh BR. The mechanistic classification of ptosis. Ophthalmology. 1980;87(10):1019–21.PubMedGoogle Scholar
  3. 3.
    Heidary G, Engle EC, Hunter DG. Congenital fibrosis of the extraocular muscles. Semin Ophthalmol. 2008;23(1):3–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Allen CE, Rubin PA. Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES): clinical manifestation and treatment. Int Ophthalmol Clin. 2008;48(2):15–23.CrossRefPubMedGoogle Scholar
  5. 5.
    De Baere E. Blepharophimosis, ptosis and epicanthus inversus. Gene Reviews. Initial posting 8 July 2004. Last revised 15 Feb 2006. Online at www.ncbi.nlm.nih.gov/bookshelf
  6. 6.
    Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia, and complete heart block: unusual syndrome with histologic study in one of two cases. AMA Arch Ophthalmol. 1958;60(2):280–9.PubMedGoogle Scholar
  7. 7.
    Berenberg RA, Pellock JM, DiMauro S, Schotland DL, Bonilla E, Eastwood A, et al. Lumping or splitting? “Ophthalmoplegia-plus” or Kearns-Sayre syndrome? Ann Neurol. 1977;1(1):37–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Eagle Jr RC, Hedges TR, Yanoff M. The atypical pigmentary retinopathy of Kearns-Sayre syndrome. A light and electron microscopic study. Ophthalmology. 1982;89(12):1433–40.PubMedGoogle Scholar
  9. 9.
    Young TJ, Shah AK, Lee MH, Hayes DL. Kearns-Sayre syndrome: a case report and review of cardiovascular complications. Pacing Clin Electrophysiol. 2005;28(5):454–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Lauwers MH, Van Lersberghe C, Camu F. Inhalation anaesthesia and the Kearns-Sayre syndrome. Anaesthesia. 1994;49(10):876–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Egger J, Wilson J. Mitochondrial inheritance in a mitochondrially mediated disease. N Engl J Med. 1983;309(3):142–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Leveille AS, Newell FW. Autosomal dominant Kearns-Sayre syndrome. Ophthalmology. 1980;87(2):99–108.PubMedGoogle Scholar
  13. 13.
    Ogasahara S, Yorifuji S, Nishikawa Y, Takahashi M, Wada K, Hazama T, et al. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology. 1985;35(3):372–7.PubMedGoogle Scholar
  14. 14.
    Thornton C. The myotonic dystrophies. Semin Neurol. 1999;19(1):25–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Meola G, Moxley 3rd RT. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol. 2004;251(10):1173–82.CrossRefPubMedGoogle Scholar
  16. 16.
    Oya Y, Yoshida H, Takeshima M, Toyama J, Shigeto H, Ogawa M, et al. Beneficial effect of eyelid makeup (natural rubber latex) to induce a new fold in the treatment of blepharoptosis in myotonic dystrophy. Rinsho Shinkeigaku. 2000;40(5):483–6.PubMedGoogle Scholar
  17. 17.
    Codere F, Brais B, Rouleau G, Lafontaine E. Oculopharyngeal muscular dystrophy: what’s new? Orbit. 2001;20(4):259–66.CrossRefPubMedGoogle Scholar
  18. 18.
    Blumen SC, Korczyn AD, Lavoie H, Medynski S, Chapman J, Asherov A, et al. Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation in the PABP2 gene. Neurology. 2000;55(9):1267–70.PubMedGoogle Scholar
  19. 19.
    Tome FM, Chateau D, Helbling-Leclerc A, Fardeau M. Morphological changes in muscular fibers in oculopharyngeal muscular dystrophy. Neuromuscul Disord. 1997;7 Suppl 1:S63–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O’Donovan DG, et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med. 2005;11(6):672–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Davies JE, Sarkar S, Rubinsztein DC. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet. 2006;15(1):23–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Chartier A, Raz V, Sterrenburg E, Verrips CT, van der Maarel SM, Simonelig M. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Hum Mol Genet. 2009;18(10):1849–59.CrossRefPubMedGoogle Scholar
  23. 23.
    Verheesen P, de Kluijver A, van Koningsbruggen S, de Brij M, de Haard HJ, van Ommen GJ, et al. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum Mol Genet. 2006;15(1):105–11.CrossRefPubMedGoogle Scholar
  24. 24.
    Molgat YM, Rodrigue D. Correction of blepharoptosis in oculopharyngeal muscular dystrophy: review of 91 cases. Can J Ophthalmol. 1993;28(1):11–4.PubMedGoogle Scholar
  25. 25.
    De Swart BJ, van der Sluijs BM, Vos AM, Kalf JG, Knuijt S, Cruysberg JR, et al. Ptosis aggravates dysphagia in oculopharyngeal muscular dystrophy. J Neurol Neurosurg Psychiatry. 2006;77(22):266–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Coiffier L, Perie S, Laforet P, Eymard B, St Guily JL. Long-term results of cricopharyngeal myotomy in oculopharyngeal muscular dystrophy. Otolaryngol Head Neck Surg. 2006;135(2):218–22.CrossRefPubMedGoogle Scholar
  27. 27.
    Burde RM, Savino PJ, Trobe JD. Eyelid disturbances in clinical decisions in neuro-ophthalmology. 3rd ed. St. Louis: Mosby Publishers; 2002.Google Scholar
  28. 28.
    Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16(7):459–67.CrossRefPubMedGoogle Scholar
  29. 29.
    Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am. 2008;22(3):509–26.CrossRefPubMedGoogle Scholar
  30. 30.
    Marino M, Barbesino G, Pinchera A, Manetti L, Ricciardi R, Rossi B, et al. Increased frequency of euthyroid ophthalmopathy in patients with Graves’ disease associated with myasthenia gravis. Thyroid. 2000;10(9):799–802.CrossRefPubMedGoogle Scholar
  31. 31.
    Antonio-Santos AA, Eggenberger ER. Medical treatment options for ocular myasthenia gravis. Curr Opin Ophthalmol. 2008;19(6):468–78.CrossRefPubMedGoogle Scholar
  32. 32.
    Bradley EA, Bartley GB, Chapman KL, Waller RR. Surgical correction of blepharoptosis in patients with myasthenia gravis. Ophthal Plast Reconstr Surg. 2001;17(2):103–10.CrossRefPubMedGoogle Scholar
  33. 33.
    Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003;48(1):12–38.CrossRefPubMedGoogle Scholar
  34. 34.
    Dinges WL, Witherspoon SR, Itani KM, Garg A, Peterson DM. Blepharoptosis and external ophthalmoplegia associated with long-term antiretroviral therapy. Clin Infect Dis. 2008;47(6):845–52.CrossRefPubMedGoogle Scholar
  35. 35.
    Fraunfelder FW, Richards AB. Diplopia, blepharoptosis and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology. 2008;115(12):2282–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Song A, Carter KD, Nerad JA, Boldt C, Folk J. Steroid-induced ptosis: case studies and histopathologic analysis. Eye (Lond). 2008;22(4):491–5.Google Scholar
  37. 37.
    Wong VA, Beckingsale PS, Oley CA, Sulivan TJ. Management of myogenic ptosis. Ophthalmology. 2002;109(5):1023–31.CrossRefPubMedGoogle Scholar
  38. 38.
    Patel SM, Linberg JV, Sivak-Callcott JA, Gunel E. Modified tarsal resection operation for congenital ptosis with fair levator function. Ophthal Plast Reconstr Surg. 2008;24(1):1–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Esmaeli B, Chung H, Pashby RC. Long-term results of frontalis suspension using irradiated, banked fascia lata. Ophthal Plast Reconstr Surg. 1998;14(3):159–63.CrossRefPubMedGoogle Scholar
  40. 40.
    Salvi SM, Currie ZI. Frontalis suspension sling using palmaris longus tendon in chronic progressive external ophthalmoplegia. Ophthal Plast Reconstr Surg. 2009;25(2):140–1.CrossRefPubMedGoogle Scholar
  41. 41.
    Goldey SH, Baylis HI, Goldberg RA, Shorr N. Frontalis muscle flap advancement for correction of blepharoptosis. Ophthal Plast Reconstr Surg. 2000;16(2):83–93.CrossRefPubMedGoogle Scholar
  42. 42.
    Carter SR, Meecham WJ, Seiff SR. Silicone frontalis slings for the correction of blepharoptosis: indications and efficacy. Ophthalmology. 1996;103(4):623–30.PubMedGoogle Scholar
  43. 43.
    Bagheri A, Aletaha M, Saloor H, Yazdani S. A randomized clinical trial of two methods of fascia lata suspension in congenital ptosis. Ophthal Plast Reconstr Surg. 2007;23(3):217–21.CrossRefPubMedGoogle Scholar
  44. 44.
    Kersten RC, Bernardini FP, Khouri L, Moin M, Roumeliotis AA, Kulwin DR. Unilateral frontalis sling for the correction of unilateral poor-function ptosis. Ophthal Plast Reconstr Surg. 2005;21(6):412–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Maine Eye CenterPortlandUSA

Personalised recommendations